Evaluation of malignant potential based on single infection status with high-risk human papillomaviruses 16, 52, and 58 in the uterine cervix.

Juhun Lee; Yujin Heo; Hyun-Jung Lee

Objective: High-risk human papillomavirus (HR-HPV) is known as the most important carcinogen in uterine cervical carcinoma. Previous studies have evaluated genotype-specific risk for carcinogenesis. However, the genotype-specific risk remains still unclear due to some limitations of those studies. This study aimed to evaluate the malignant potential of the three most prevalent HR-HPVs in Korea. Methods: Patients who underwent cervical conization were included. They had received HPV test within a year before the surgery and those exhibiting concurrent multiple infections with HR-HPVs were excluded. Of single infections with HR-HPV, the three most prevalent HR-HPVs were included to analyze. The carcinoma in situ (CIS) in the final diagnosis included some cervical intraepithelial neoplasia 3 (CIN3) cases, which had been diagnosed with CIS. To evaluate their malignant potential, CIS , including CIS and invasive carcinoma, was categorized in each HR-HPV group. The ratios of pathologic diagnoses and odds ratios for malignant potential were evaluated between the three most prevalent HR-HPVs. Results: Totally 230 patients were found to have a single infection with HR-HPV16, HR-HPV52, or HR-HPV58. The HPV16 group did not exhibit a significantly more CIS, invasive carcinoma, and CIS than HPV52 or HPV58. In the logistic regression analyses, in the evaluation of the malignant potential (CIS ), no significant difference was observed between the three single HR-HPV infection groups. Conclusion: Gynecologists should pay attention to not only HPV16 but also HPV52 and HPV58 because these genotypes have similar malignant potential. These findings support the need for a nine-valent vaccine against HR-HPVs in Korea.

HUMAN papillomavirus; CERVIX uteri; CERVICAL intraepithelial neoplasia; LOGISTIC regression analysis; GENITAL warts; CARCINOMA in situ

Journal of Gynecologic Oncology, 2024, Vol 35, p39

2005-0380

Academic Journal

10.3802/jgo.2024.35.S2.P37